Search
Doxercalciferol
go.drugbank.com/drugs/DB06410ApprovedInvestigationalDoxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients … Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin
Difelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigationalDifelikefalin (CR845) is an agonist of kappa opioid receptors (KORs) useful in the treatment of pruritus secondary to chronic kidney disease. KORs were first associated with itching in 1984. … [A237615,A237620] The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes
Lipoic acid
go.drugbank.com/drugs/DB00166ApprovedInvestigationalNutraceuticalA vitamin-like antioxidant.
Categories: Compounds used in a research, industrial, or household setting, Vitamin B ComplexRimantadine
go.drugbank.com/drugs/DB00478ApprovedAn RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.
Nicoboxil
go.drugbank.com/drugs/DB12911ApprovedWithdrawnDespite topical nicoboxil/nonivamide topical analgesic medication being used since the 1950s, recent studies demonstrate continued interest in the medication(s) given its demonstrated efficacy, safety, … Such combination topical analgesics are only available for purchase and use (for humans) in some parts of Europe and Asia, like Germany and Australia [F11, F16].
Methylene blue
go.drugbank.com/drugs/DB09241ApprovedInvestigationalHistorically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. … Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early
Mixtures: UR N-C Urinary AntisepticCerliponase alfa
go.drugbank.com/drugs/DB13173ApprovedInvestigational[L51329] CLN2 is a predominantly pediatric-onset neurodegenerative disease caused by a deficiency in the lysosomal enzyme TPP1, leading to progressive impairment in motor and cognitive function. … [A264354, A264369] As a recombinant human TPP1, cerliponase alfa is used as an enzyme replacement therapy to restore the levels of TPP1 in patients with CLN2.[L51339]
Categories: Hydrolytic Lysosomal N-terminal Tripeptidyl PeptidaseGadolinium
go.drugbank.com/drugs/DB12091ApprovedInvestigationalWithdrawnGadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease.
Categories: Compounds used in a research, industrial, or household settingEvening primrose oil
go.drugbank.com/drugs/DB11358ApprovedNutraceuticalIn its composition it presents some fatty acids such as [DB00132] and [DB13854]. … [L2845] By Health Canada, evening primrose oil is approved in over-the-counter combination dietary supplements.[L1113] By the EMA, evening primrose oil is approved in herbal preparations.[L2851]
Mixtures: PRIM E CAPSULE, Evening Primrose Oil With Vitamin ECategories: Complex MixturesZilganersen
go.drugbank.com/drugs/DB18161ApprovedInvestigational[L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons … [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition